Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35510595/
Solid clinical data support the current recommendations to use empagliflozin or dapagliflozin in HFrEF. The underlying mechanisms likely include changes in cardiac and intrarenal haemodynamic. Yet, these mechanisms do not...
Conclusions: Solid clinical data support the current recommendations to use empagliflozin or dapagliflozin in HFrEF. The underlying mechanisms likely include changes in cardiac and intrarenal haemodynamic. Yet, these mechanisms do not seem to solely explain the observed magnitude of clinical effect with SGLT2 inhibitors in HFrEF and other...
Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: Five Japanese cases - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35501824/
Empagliflozin showed some positive effects in 4 cases with better renal function than CKD stage 4. Further studies will be required to clarify the efficacy and safety of SGLT2 inhibitors...
Conclusion: Empagliflozin showed some positive effects in 4 cases with better renal function than CKD stage 4. Further studies will be required to clarify the efficacy and safety of SGLT2 inhibitors in a larger group of patients with similar medical conditions.
-
Heart Failure Connect4yrKey Points • Source: BMC Nephrology • Conclusion: “Empagliflozin showed some positive effects in 4 cases with better renal function than CKD [chronic kidney disease] stage 4. Further studies will Show More
Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35512448/
doi: 10.1093/jpp/rgac022. Online ahead of print. 1 Department of Natural Products, National Institute of Pharmaceutical Education and Research (NIPER), Kolkata, Chunilal Bhawan 168, Maniktala Main Road, Kolkata, West Bengal, India....
Conclusion: There was a significant change in the AUC0-t and Cmax of ATR, ALO and EMPA after co-administration with Acai berry. Further studies are recommended to confirm the clinical significance of these interactions.
The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial
Source : https://www.sciencedirect.com/science/article/pii/S0002870322000837?via=ihub
Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve cardiac structure but most studies suggest no change in left ventricular (LV) systolic function at rest. Whether SGLT2 inhibitors improve LV contractile reserve is unknown....
Conclusions: Empagliflozin for 12 weeks added to guideline-directed HF therapy did not improve LV contractile reserve in patients with HFrEF.
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35475341/
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) mitigate cardiovascular risk in individuals with type 2 diabetes, but most eligible patients do not receive them. We characterized...
Conclusions: While use of SGLT2is and GLP-1RAs by cardiologists in the United States increased substantially over a 6-year period, cardiologists still account for a very small proportion of all use, contributing to marked undertreatment of individuals with type 2 diabetes at high cardiovascular risk.
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
Katherine R. Tuttle, Adeera Levin, Masaomi Nangaku, Takashi Kadowaki, Rajiv Agarwal, Sibylle J. Hauske, Amelie Elsäßer, Ivana Ritter, Dominik Steubl, Christoph Wanner, David C. Wheeler; Safety of Empagliflozin in Patients...
Conclusions: Use of empagliflozin in patients with type 2 diabetes and advanced CKD raised no new safety concerns and may have beneficial effects on the development of hyperkalemia and edema.
The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study
Source : https://www.e-dmj.org/journal/view.php?doi=10.4093/dmj.2021.0373
The Efficacy of Treatment Intensification by Quadruple Oral Therapy Compared to GLP-1RA Therapy in Poorly Controlled Type 2 Diabetes Mellitus Patients: A Real-world Data Study Minyoung Kim 1
Conclusion/Relevance: We compared the glycemic efficacy of treatment intensification between quadruple oral antidiabetic drug therapy and once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA)-based triple therapy in patients with poorly controlled type 2 diabetes mellitus refractory to triple oral therapy.
Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin - Heart Failure Reviews
Source : https://link.springer.com/article/10.1007/s10741-022-10228-8
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent syndrome with multifaceted pathophysiology. All approaches to neurohormonal modulation were shown not to improve survival in HFpEF, despite their...
Relevance: This paper recapitulates the journey from the failure of trials on neurohormonal antagonists to the attempts of personalized approaches and the new perspectives of SGLT2i therapy for HFpEF.
Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
Source : https://www.frontiersin.org/articles/10.3389/fcvm.2022.869272/full
BackgroundThe efficacy of dapagliflozin and empagliflozin in sodium-glucose cotransport-2 inhibitors (SGLT-2i) in patients with heart failure (HF) has been discovered. However, which drug could improve varied prognostic outcomes has not...
Recommendations: Overall, 10 mg/day dapagliflozin may be the optimal recommendation for its premium and comprehensive effect on improving the prognosis of patients with HF compared to 10 mg/day empagliflozin.
In Brief: Expanded Heart Failure Indication for Empagliflozin (Jardiance) | The Medical Letter, Inc.
Source : https://secure.medicalletter.org/w1648a
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin ( Jardiance - Boehringer Ingelheim) was approved by the FDA in 2021 to reduce the risk of hospitalization for heart failure (HF) and...
CONCLUSION: Addition of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) to standard treatment for heart failure with preserved ejection fraction reduced the composite risk of hospitalization for heart failure or cardiovascular death in patients with an LVEF >40%, with or without type 2 diabetes....
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) in kidney transplant recipients: what is the evidence? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35450095/
1 Renal Section, Department of Medicine, Boston University School of Medicine, Boston, MA, USA. 2 Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 3 Assistant Professor...
Conclusion: In this review, we will discuss the known mechanisms SGLT2i exploit to provide their beneficial effects, the potential benefits, and risks of these agents in the context of kidney transplantation, and finally, we will discuss current findings of the published literature for SGLT2i use in kidney transplant recipients and propose...
Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35443373/
Overall, FDC of Remogliflozin Etabonate + Vildagliptin added on to Metformin was found to be efficacious and well tolerated in the treatment of patients with T2DM, and demonstrated non-inferiority to...
Conclusion: Overall, FDC of Remogliflozin Etabonate Vildagliptin added on to Metformin was found to be efficacious and well tolerated in the treatment of patients with T2DM, and demonstrated non-inferiority to Empagliflozin 25mg Linagliptin 5mg treatment added on to Metformin.
" the team did not find that cardiometabolic risk factors explained the link between infertility with heart failure in this study"
Study finds infertility history linked with increased risk of heart failure
Source : https://medicalxpress.com/news/2022-04-infertility-history-linked-heart-failure.html
A new study finds that a history of infertility is associated with increased risk of heart failure. Published in the Journal of the American College of Cardiology, researchers from Massachusetts...
The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35345249/
Sodium-glucose co-transporter (SGLT)-2 inhibitors were initially developed for management of type 2 diabetes but have been shown to offer improved outcomes in heart failure, a condition in which concomitant chronic...
Relevance: In this review we discuss in detail the evidence for SGLT2 inhibitors in heart failure, particularly with regard to kidney health.
Conclusions: Initiation of empagliflozin in patients hospitalized for AHF produced clinical benefit regardless of the degree of symptomatic impairment at baseline; and improved symptoms, physical limitations and quality of life, with benefits seen as early as 15 days and maintained through 90 days.
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35413307/
Heart failure (HF) is a clinical syndrome with symptoms and or signs caused by a structural and/or functional cardiac abnormality and associated with elevated natriuretic peptide levels and/or objective evidence...
Conclusion: This review focuses the recent advances in the pharmacological agents for treatment of chronic heart failure, including their mechanisms of action, the evidence based on the clinical trials, and the guideline recommendations for their use.
Conclusion/Relevance: Empagliflozin now has FDA approval for reducing cardiovascular death or hospitalization among patients with heart failure with preserved left ventricular ejection fraction, defined as more than 40%, with or without diabetes.
Mode of Action and Human Relevance Assessment of Male CD-1 Mouse Renal Adenocarcinoma Associated With Lifetime Exposure to Empagliflozin - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35393688/
Inhibition of sodium-glucose cotransporter-2 (SGLT2) has been shown to be a safe and efficacious approach to support managing Type 2 diabetes. In the 2-year carcinogenicity study with the SGLT2 inhibitor...
Conclusions and Implications: Considering that empagliflozin is not genotoxic in the standard battery of genotoxicity tests, and not all five key events are present in the context of female mice, rats or humans, nor for other osmotic diuretics or other SGLT2 inhibitors, the observed male mouse renal tumors are not considered relevant to humans.
Nationwide Trends in Dispensing of Sodium Glucose Cotransporter 2 Inhibitors
Source : https://www.cjhp-online.ca/index.php/cjhp/article/view/3066
Michael Fralick Sinai Health System, University of Toronto Diana Martins Unity Health Toronto Mina Tadrous Women's College Research Institute, Women's College Hospital; ICES; University of Toronto Tara Gomes Unity Health...
Conclusions: The cardiovascular outcome trials appeared to have an important impact on the dispensing of SGLT2 inhibitors in Canada.
Twenty-Four Hour Blood Pressure Response to Empagliflozin and Its Determinants in Normotensive Non-diabetic Subjects - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35391843/
doi: 10.3389/fcvm.2022.854230. 1 Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. 2 Service of Endocrinology, Diabetes and Metabolism, Lausanne University Hospital,...
Conclusion: SGLT2 inhibition lowers daytime and nighttime ambulatory systolic and diastolic BP in normotensive non-diabetic subjects. Twenty-four jour changes are pronounced and comparable to those described in diabetic or hypertensive subjects. Baseline ambulatory BP was the only identified determinant of systolic and diastolic BP response....